Determinations. 

Deadline. 

## TITLE V—INCREASING COMMUNICA- TION IN MEDICAL COUNTERMEASURE ADVANCED RESEARCH AND DEVELOP- MENT 

## SEC. 501. MEDICAL COUNTERMEASURE BUDGET PLAN. 

Section 2811(b)(7) (42 U.S.C. 300hh–10(b)(7)) is amended— 

(1) in the matter preceding subparagraph (A), by striking ‘‘March 1’’ and inserting ‘‘March 15’’; 

(3) by redesignating subparagraphs (D) and (E) as subpara- graphs (E) and (F), respectively; and 

## SEC. 502. MATERIAL THREAT AND MEDICAL COUNTERMEASURE NOTIFICATIONS. 

(a) CONGRESSIONAL NOTIFICATION OF MATERIAL THREAT DETER- MINATION.—Section 319F–2(c)(2)(C) (42 U.S.C. 247d–6b(c)(2)(C)) is amended by striking ‘‘The Secretary and the Homeland Security Secretary shall promptly notify the appropriate committees of Con- gress’’ and inserting ‘‘The Secretary and the Secretary of Homeland Security shall send to Congress, on an annual basis, all current material threat determinations and shall promptly notify the Com- mittee on Health, Education, Labor, and Pensions and the Com- mittee on Homeland Security and Governmental Affairs of the Senate and the Committee on Energy and Commerce and the Com- mittee on Homeland Security of the House of Representatives’’. 

(b) CONTRACTING COMMUNICATION.—Section 319F– 2(c)(7)(B)(ii)(III) (42 U.S.C. 247d–6b(c)(7)(B)(ii)(III)) is amended by adding at the end the following: ‘‘The Secretary shall notify the 

(2) in subparagraph (A)— 

(A) in clause (ii), by striking ‘‘; and’’ and inserting ‘‘;’’; and 

(B) by striking clause (iii) and inserting the following: 

‘‘(iii) procurement, stockpiling, maintenance, and potential replenishment (including manufacturing capabilities) of all products in the Strategic National Stockpile; 

‘‘(iv) the availability of technologies that may assist in the advanced research and development of counter- measures and opportunities to use such technologies to accelerate and navigate challenges unique to countermeasure research and development; and 

‘‘(v) potential deployment, distribution, and utiliza- tion of medical countermeasures; development of clin- ical guidance and emergency use instructions for the use of medical countermeasures; and, as applicable, potential postdeployment activities related to medical countermeasures;’’; 

(4) by inserting after subparagraph (C), the following: 

‘‘(D) identify the full range of anticipated medical countermeasure needs related to research and development, procurement, and stockpiling, including the potential need for indications, dosing, and administration technologies, and other countermeasure needs as applicable and appro- priate;’’. 

